Jay Bhattacharya appointed acting CDC director
Analysis based on 26 articles · First reported Feb 18, 2026 · Last updated Feb 18, 2026
The leadership changes at the United States===Centers for Disease Control and Prevention (CDC) and United States===United States Department of Health and Human Services (HHS) signal a shift in public health policy, particularly regarding vaccine recommendations and pandemic response. This could impact pharmaceutical and biotechnology companies, as well as public trust in health agencies, potentially leading to volatility in related market sectors.
Jay Bhattacharya, currently the director of the United States===National Institutes of Health (NIH), has been appointed as the acting director of the United States===Centers for Disease Control and Prevention (CDC). This move is part of a broader leadership shake-up within the United States===United States Department of Health and Human Services (HHS) orchestrated by Health Secretary Robert F. Kennedy Jr. and the Trump administration. Bhattacharya replaces Jim O'Neill, who stepped down from both his acting CDC role and as deputy secretary of HHS and is expected to be nominated to lead the United States===National Science Foundation. The changes follow the ouster of former CDC director Susan Monarez, who clashed with Kennedy over vaccine policies. Bhattacharya is known for his criticism of past pandemic responses and co-authored the Great Barrington Declaration, advocating for an end to COVID lockdowns. The restructuring aims to align federal health policy with the administration's priorities ahead of the midterm elections, with a shift in focus from vaccine mandates to other health issues like healthy eating. The NIH has also faced budget cuts and staff reductions under the current administration.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard